Journal of Gastrointestinal & Digestive System
Open Access

Abstract

ST2/IL33 signaling pathway has been related to many inflammatory disorders as well as inflammatory bowel disease (IBD). IL-33, a member of the IL-1 family, is expressed in endothelial and epithelial cells and regulates gene transcription upon its nuclear translocation. IL-33 is released during necrosis episodes and its precursor is enzymatically processed to promote an inflammatory response as a damage-associated molecular pattern or alarmin. The IL-33 receptor ST2, encoded by IL1RL1, is expressed as both a membrane-anchored receptor (ST2L) activated by IL-33 and as a soluble variant (sST2) that behaves as a decoy receptor in inflammatory conditions and we proposed as a prognostic disease biomarker. We characterized the IL33/ST2 system in mucosa from IBD patients and the effect of clinical course and therapy on sST2 content and cellular distribution as predictive markers of response to treatment, disease activity and outcome. Additional findings demonstrate the molecular and cellular mechanisms that regulate mucosa inflammation. This conference will propose cutting-edge biomedical data on recent advances in the role of ST2 in IBD.

Biography

Email: mhermoso@med.uchile.cl